Treatment Patterns of Neratinib in HER2+ EBC in China

Anlotinib Combined With Chemotherapy for the Treatment of HER2 Negative Advanced Breast Cancer

NCT05334147 ·Status: UNKNOWN

A Study to Describe the Real-world Treatment Patterns and Associated Outcomes in Patients of China With HER2-positive Unresectable or Metastatic Breast Cancer

NCT05769751 ·Status: COMPLETED

Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer

NCT04158505 ·Status: UNKNOWN

A Retrospective Observational Study of Patients With Early-stage HER2-positive Breast Cancer, Treated With Neratinib

NCT05599334 ·Status: COMPLETED

Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer

NCT00300781 ·Status: COMPLETED ·Phase: PHASE2

A Real-world Clinical Study of Pyrotinib Maleate Tablets in the Treatment of Breast Cancer Patients With Positive Her-2

NCT03908749 ·Status: UNKNOWN

Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer

NCT05558722 ·Status: UNKNOWN ·Phase: PHASE2

Adjuvant Therapy With Neratinib in HER2 Positive Early Breast Cancer

NCT06693024 ·Status: RECRUITING

A Study to Evaluate the Efficacy and Safety of Oral Navelbine in Female Patients With HER2-Negative Metastatic Breast Cancer

NCT03854617 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

NCT05334810 ·Status: UNKNOWN ·Phase: PHASE2

A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast Cancer

NCT05629949 ·Status: COMPLETED ·Phase: PHASE3

Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

NCT03412383 ·Status: UNKNOWN ·Phase: PHASE2

Study of TFX06 in Women With Advanced Breast Cancer.

NCT05927779 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer

NCT05263882 ·Status: UNKNOWN ·Phase: PHASE2

Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer

NCT01937689 ·Status: COMPLETED ·Phase: PHASE1

A Phase 1/2 Study Of HKI-272 (Neratinib) in Combination With Trastuzumab (Herceptin) In Subjects With Advanced Breast Cancer

NCT00398567 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression

NCT07047443 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Real-world Efficacy and Safety Study of Amlotinib for HER2-negative Advanced Breast Cancer

NCT06340165 ·Status: RECRUITING

Pyrotinib After Trastuzumab-based Adjuvant Therapy in Patients With HER2-positive Breast Cancer

NCT05880927 ·Status: RECRUITING ·Phase: PHASE2

Study Evaluating Neratinib Plus Paclitaxel VS Trastuzumab Plus Paclitaxel In ErbB-2 Positive Advanced Breast Cancer

NCT00915018 ·Status: COMPLETED ·Phase: PHASE2

Pyrotinib in HER2-positive Early Breast Cancer

NCT06718335 ·Status: NOT_YET_RECRUITING ·Phase: NA

Continuous or Intermittent Extension of Adjuvant Pyrotinib for Invasive HER2-positive Breast Cancer

NCT05910398 ·Status: RECRUITING ·Phase: PHASE3

The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study

NCT06254690 ·Status: RECRUITING ·Phase: PHASE2

Study Evaluating HKI-272 in Tumors

NCT00146172 ·Status: COMPLETED ·Phase: PHASE1

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

NCT05594095 ·Status: RECRUITING ·Phase: PHASE2